NCT05786924View on ClinicalTrials.gov

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosisMelanomaMelanoma (Skin)BRAF Gene MutationBRAF V600EBRAF V600 MutationBRAF Mutation-Related TumorsBRAFMetastatic Lung Non-Small Cell CarcinomaMetastatic MelanomaMetastatic Lung CancerRecurrent MelanomaRecurrent Lung CancerRecurrent Lung Non-Small Cell CarcinomaNSCLCSolid TumorSolid CarcinomaKRAS G12DKRAS G12VKRAS Mutation-Related TumorsNRAS Gene MutationThyroid CancerThyroid CarcinomaColorectal CancerColorectal CarcinomaRecurrent Histiocytic and Dendritic Cell NeoplasmBrain MetastasesRecurrent NSCLCKRAS G13CAcquired Resistance to KRAS G12C InhibitorKRAS G12AKRAS G12FKRAS G12RKRAS G13D
Interventions
DRUG

BDTX-4933

RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

20007

RECRUITING

Georgetown University Lombardi Cancer Center, Washington D.C.

22031

RECRUITING

NEXT Virginia, Fairfax

49546

RECRUITING

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

55455

RECRUITING

Masonic Cancer Center University of Minnesota, Minneapolis

63130

RECRUITING

Washington University, St Louis

80045

RECRUITING

University of Colorado - Aurora Cancer Center, Aurora

85234

RECRUITING

Banner Health- MD Anderson Cancer Center, Gilbert

98109

RECRUITING

Fred Hutchinson Cancer Research Center, Seattle

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Institut de Recherches Internationales Servier

OTHER